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INTRODUCTION 
 
Amounting to a third of total mortality at present, cardiovascular mortality has been a 
leading cause of death worldwide. Compared to cancerous diseases, it is of approximately 
the same incidence in the developed countries. On launching the world’s first prospective 
comprehensive study on the aetiology and risk factors of cardiovascular diseases in the USA, 
attention was focussed on the follow-up of the health state of the citizens of Framingham, a 
small provincial town.  As a result, the role of blood lipids, the importance of diabetes, 
hypertension and smoking, an unequivocally harmful factor, in the development of 
atherosclerosis were confirmed. Current research into cardiovascular diseases is devoted to 
underlying genetic abnormalities. 
Cardiovascular pathophysiology may manifest itself in several diseases of varying severity. 
Usually, risk factors appear first and the process may end up in myocardial infarction, stroke 
or the obstruction of arteries in the limbs. In the necrotized area, remodelling of the 
connective tissues is observed, which may lead to the failure of the affected organ, e.g. 
cardiac failure over time. In approximately 5-15 years on average, such diseases may cause 
the patient’s death. Patients with ischaemic cardiomyopathy pose an increasingly great 
problem for society as, due to the spread of primary coronary intervention, there has been a 
spectacular decrease in mortality rates associated with acute myocardial infarction 
worldwide, but surviving patients make up the vast majority of the population with cardiac 
failure.  
Currently, several methods are at our disposal to treat the ischaemic myocardium. The basic 
therapeutic arsenal includes treatment with medicines such as acetylsalicylic acid, beta-
blockers, Ca+2 channel blockers and If – inhibitors. Symptomatic treatment is provided by 
giving nitrate therapy continuously or in unexpected attacks. Angiotensin converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARB), statins to decrease cholesterol 
synthesis and ezetimibe to inhibit cholesterol absorption also form the base of prophylactic 
therapy. Trimetazidine is also used in symptomatic treatment to “strengthen” aerobic 
metabolism in the mitochondria. Having confirmed coronary sclerosis the physician can 
supplement the aforementioned medicinal treatment with invasive therapeutic procedures 
(percutaneous coronary angioplasty and coronary bypass surgery) to treat ischaemia. 
How does the renin-angiotensin-aldosterone system (RAAS) function? 
As a result of efforts put into research activities, physicians have explored the renin-
angiotensin-aldosterone system (RAAS) and studied its aspects in detail.  Actually, RAAS 
functions as a hormonal system controlling the salt and water balance of the body and blood 
pressure. 
In the first step of the process, renin, a protease produced by the juxtaglomerular cells of the 
kidney, splits off Angiotensin I (decapeptide) from the N-terminal end of angiotensinogen 
(alpha2-globulin) synthesized in the liver. Conversion of Angiotensin I into Angiotensin II is 
catalyzed by the angiotensin converting enzyme (ACE), which is also a protease. Splitting two 
amino acids off the Angiotensin I (Ang I) C terminal, ACE “creates” Angiotensin II (Ang II) 
octapeptide. Since ACE also plays a role in other processes, e.g. it inactivates bradykinine, it 
is also referred to as kininase. Alternatively, the conversion of Ang I into Ang II can take place 
differently from ACE, e.g. by chymase.  Ang II binds with the cells’ type 1 Angiotensin II 
receptors (AT1R) and type 2 Angiotensin II receptors (AT2R). 
Ang II has opposite effects on the two receptors, although the activating effect of AT2R is 
negligible compared to that of AT1R. Ang II triggers vasoconstriction in the cardiovascular 
system in both the AT1 receptors of arteries and veins via the intracellular inositol and G-
protein pathways. Ang II also has a prothrombolytic effect by interfering with the adhesion 
and aggregation of thrombocytes. Of the many effects of Ang II, the most important ones 
include the following: it causes hypertrophy in smooth muscle and myocardial cells, 
accelerates the progression of hypertension and atherosclerosis and starts off a thrombotic 
cascade in endothelial injuries through the activation of thrombocytes. Also affecting AT1R, 
Ang II enhances aldosterone release by the adrenal cortex contributing to increased renal 
Na+ retention and K+ secretion. It can cause weak constriction in the renal arteries and 
afferent arterioles but stronger vasoconstriction in the efferent ones. It can increase the 
sensitivity of tubuloglomerular feedback and decrease blood flow through the renal medulla. 
By contracting mesangial cells, it decreases the surface for secretion. Studies have confirmed 
that cellular migration, growth and connective tissue remodelling, i.e. the progression of 
fibrosis, increase on AT1R due to the effect of Ang II. Ang II has opposite effects on AT2R; it 
increases the production of NO and induces vasodilation.  Aminopeptidase A splits Ang II 
into angiotensin III, which is further split by aminopeptidase M into angiotensin IV, a 
biologically less effective substance. Angiotensin converting enzyme 2 (ACE 2) is one of the 
youngest members of RAAS; it can split both Ang I and Ang II thus decreasing the quantity of 
substrates. On Mas receptors, the resulting angiotensin 1-7 (Ang 1-7) usually generates 
opposite responses to the effect mediated by Ang II on AT1R. Ang 1-7 can improve 
inflammatory and fibrotic processes in several organs, e.g. lungs, kidneys and liver. It also 
has favourable effects on metabolism by improving glucose uptake and lipolysis, resulting in 
lowered insulin resistance and dyslipidaemia. 
 
Interfering with RAAS by using medication 
The complicated RAAS system outlined above is of physiologically enormous importance. 
Interfering at different points of the system has been a major preoccupation for researchers 
for some time now. As a result,  populous families of ACE inhibitors and angiotensin receptor 
blockers were discovered. The latest development in this field was the discovery of direct 
renin  inhibitors of which aliskiren was introduced into daily medical practice. 
 
The first ACE inhibitor, captopril, was introduced in the late 1970s. Since then, at least 16 
ACE inhibitors have appeared in the market worldwide. They can be divided into three 
chemical groups, such as compounds containing sulfhydryl, dicarboxylate and  phosphonate 
groups. Much of the developed drugs are so-called prodrugs. Captopril and lisinopril, 
however,  are active agents. Various ACE inhibitors may differ from one another based on 
the duration of inhibiting circulating ACE and the degree to which they can inhibit ACE in the 
tissues. ACE inhibition in the tissues in equipotent doses is multifactorial, the binding 
strength to  ACE’s terminal C and dissociation kinetics of the inhibitory molecule as well as 
the extent of  tissue penetration by the ACE inhibitor and its lipophilicity being some of the 
factors. Although extensive information is available about the function and elements of 
RAAS in blood circulation, many researchers think that the medical importance of RAAS 
modulation is due to the little-known renin-angiotensin-aldosterone system in tissues, which 
was described as early as the 1980s. While a decrease of 20%  in primary end-point could be 
detected in studies on perindopril and ramipril, trials using trandolapril and quinapril, 
substances of greater tissue activity given in secondary prevention, did not exhibit a 
significant effect on  survival or the prevention of  coronary events.  In the latter cases, 
differences in the tissue affinity of ACE inhibitors may be detected in the background. 
The efficiency of ACE inhibitors has been demonstrated in several clinical studies on large 
samples. These inhibitors decrease the incidence of cardiovascular death, non-fatal 
myocardial infarction or cardiac arrest in stable coronary disease; they improve the 
prognosis of myocardial infarction, inhibit the process of left ventricular remodelling, delay 
the development of hypertension and reduce left ventricular mass index in left ventricular 
hypertrophy. In addition, ACE inhibitors reduce the chances of nephropathy to develop, 
incidence of microalbuminuria and likelihood of newly diagnosed diabetes. The latest 
therapeutic guidelines take the above for granted; that is how ACE inhibitors have become 
medicines recommended as basic therapeutic agents in the primary and secondary 
prevention of diseases of the highest mortality. 
Importance of the ACE genotype  
The clinical efficiency of ACE inhibitors appears to be genetically determined as, comparing 
Afro-American patients and patients of the Caucasian race, ACE inhibiting treatment has 
been less efficient in the former group. Genetic studies have highlighted that ACE expression 
in the genetic substance of ACE is controlled by insertion/deletion (I/D) polymorphism, 
which in individuals of the DD genotype results in 50% higher ACE expression than in those 
of the II genotype. Accordingly, elevated serum ACE levels in the presence of the D allele are 
suggestive of the D allele acting as a major factor of risk for cardiovascular diseases. 
Although not to a significant extent, hypertension was ten percent more commonly detected 
among patients of the DD genotype. Together with genetic differences, environmental 
factors and lifestyle and ethnic dissimilarities may all play a decisive role in the development 
of hypertension. The presence of the D allele, for example, is an independent predictor of 
ischaemic stroke in the family of cardiovascular diseases. Diabetes sufferers carrying the DD 
allele are more likely to develop nephropathy. In 2003, Sayed-Tabatabaei published a meta-
analysis based on the data of 9833 patients in 23 articles, in which the extent of 
atherosclerosis was established in view of the proportion between the tunica intima and 
tunica media in the carotid artery.  This publication reported significantly higher levels of 
atherosclerosis among patients of the DD genotype. Even more striking results were 
disclosed if cerebrovascular disease, diabetes and hypertension occurred simultaneously. 
Endogenous ACE regulation 
The issue of the potential of endogenous ACE inhibition was raised as early as the late 1970s. 
In 1979, two teams published their results independently of each other. Ryan et al detected 
a substance, capable of ACE inhibition, of approximately 10 kDA in molecular size in the 
serum and urine of guinea pigs and possums.  Klauser and his team identified human 
albumin and acetyl tryptophan, a preservative, as endogenous ACE inhibitors in a 
commercially available plasma preparation. They justified that the C-terminal of albumin 
alone had a more significant endogenous inhibitory effect than the whole protein did. In the 
1980s, four teams published their results about ACE inhibition. Among them, the results by 
Liebermann et al should be highlighted; they isolated a molecule from the sera of patients 
with sarcoidosis, exceeding 50 kD and capable of reversible inhibition, which made it difficult 
to measure ACE serum levels. After the dilution of the serum by eight times, the 
measurements could be performed. At the end of the 1990s, Thevananther et al separated a 
protein with ACE inhibiting effect of 14 kD in molecular mass using affinity chromatography 
and polyacrylamide gel electrophoresis. 
In the past few years, our team also confirmed that human serum albumin (HSA) had 
endogenous ACE inhibiting properties. HSA inhibited serum ACE activity at 5.70.7 mg/ml 
IC50 while the physiological concentration of human serum albumin fell in the range of 35-52 
mg/ml. The above data show that human serum albumin has a significant inhibitory effect 
on angiotensin converting enzyme in vivo. We have found that human serum albumin can 
stabilize angiotensin converting enzyme (ACE) activity at a very low level, independently of 
the level of ACE expression.   
Importance of coronary bypass surgery  
Coronary artery bypass grafting (CABG) is the most commonly performed cardiovascular 
surgical intervention, in which new pathways are created to replace narrowed or obstructed 
vessels in an attempt to improve the oxygen and nutriment supply to tissues with poor 
perfusion. Surgeons have used saphenous vein grafts to bypass coronary arteries since the 
1960s. They are commonly used owing to their elasticity, easy accessibility and low 
dissection rate. Unfortunately, practice has soon established that the life expectancy of 
venous grafts is relatively short; various degenerative processes may cause early 
degeneration in the first year after insertion. The ratio of graft obstruction is 15-30% and 
70% in the first postoperative year and within ten years, respectively.  Atherosclerotic 
degeneration of the grafts plays an important role, and it may differ from processes 
characteristic of the patient’s own vessels as far as duration and certain aetiological factors 
are considered. Two periods are distinguished in the literature, the first is the postoperative 
one-year period while the second is the late graft degeneration period, following the first 
postoperative year. Insufficient adaptation of the venous endothelium to increased pressure 
in the arterial system is thought to be the most important degenerative factor, as it puts   
mechanical stress on the venous system. Early graft degeneration is mainly attributed to 
technical reasons, such as perioperative damage to the venous endothelium (e.g. due to 
tension forces caused by inflation), winding course of the venous graft (it encourages the 
deposition or aggregation of thrombocytes) and disproportion between the output and 
input surfaces of venous grafts and arteries, respectively, which results in difficulty of 
unification and an increase in the shearing effect of local turbulence. Due to all of the above, 
thrombotic processes play a leading role in the first month, which is taken over by 
hyperplasia of the tunica intima in the 2nd to 12th months. After the first postoperative 
year, it is atherosclerosis that becomes the most harmful process. 
Although patients undergoing CABG operation have an increasingly higher risk, perioperative 
mortality rates are decreasing. On the other hand, it is reported that the patients’ long term 
survival after bypass surgery has not actually improved over the past 20 years. Several 
studies have been devoted to the exploration of optimal medication to slow down the 
progression of atherosclerosis in patients after bypass surgery, secondary prevention being 
in the focus of attention. Acetyl salycilic acid, beta blockers, statins and the family of ACE 
inhibitors or angiotensin receptor blockers (ARB) are baseline medicines in the postoperative 
period. 
 Whether the different types of grafts stay open or not or if they survive, depends on the 
graft’s tissue composition. The internal mammary artery exhibits the longest, occasionally 
lifelong survival. Prepared radial arteries stay permeable for 10-15 years on average. 
Saphenous veins have the poorest chance to stay open due to the aforementioned 
degenerative processes (mean: 7-9 years). According to a Canadian medical team, the 
chances for arterial and venous grafts to stay open is predictable. Enhanced graft 
degeneration is expected in diabetes sufferers, and the levels of certain biomarkers, such as 
plasma fibrinogen, creatinine and high density lipoprotein (HDL) as well as those of 
glutation-S-transferase 3, forecast increased graft degeneration. Comparing the smooth, 
short-term survival period among patients having received an internal mammary artery graft 
or a saphenous vein graft, it seems necessary to individually treat saphenous vein grafts 
after surgery in order to improve graft viability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GOALS  
 
 Checking endogenous ACE inhibition triggered by serum albumin in previous clinical 
studies. 
 Exploring the possible role of ACE inhibiting serum albumin at different ACE levels. 
 Studying the cardiovascular role of the ACE I/D polymorphism in a Hungarian sample 
of patients. 
 Identifying relationships between ACE expression and the life expectancy of vessels 
used in coronary bypass grafting in hope for finding individually tailored therapies. 
 
MATERIALS AND METHODS  
 
Ethical approval 
All of the investigations were done after approval issued by the Ethical Committee of the 
Medical and Health Science Centre at the University of Debrecen (UDMHSC REC/IEC, 2894-
2008) and the Hungarian Medical Research Council.  Every subject included in the study has 
signed an informed consent. 
Collecting blood samples, serum and DNA isolation 
Blood samples were collected in two ways; peripheral venous blood was drawn from 151 
volunteers at the outpatient unit of Department of Cardiology, UDMHSC, using the 
traditional aseptic method and collecting 1x10 ml of untreated blood and 1x5 ml blood 
treated with an anticoagulant, per person. Further samples (n=76) were obtained from 
patients undergoing bypass surgery at the Department of Cardiac Surgery, UDMHSC (1x10 
ml of untreated blood and 1x5 ml of blood treated with an anticoagulant). Serum and 
cellular fractions of the untreated samples were separated in a centrifuge and stored at -20 
°C. Genomic DNA was prepared from anticoagulated venous blood using a DNA separation 
kit (Qiagen). 
Measuring ACE activity  
ACE activity was measured according to the methods by Beneteau (Beneteau et. al. 1986)  
and Murray (Murray et. al. 2004). Briefly, ACE activity was determined at pH 8.2, using an 
artificial substrate and a reagent consisting of 25 mM HEPES, 0.5mM FAPGG, 300 mM NaCl 
and the serum in the required dilution. The examination was performed in a 96-well plate 
(Greiner-Bio One) at 37 °C. Changes in optical density (340 nm) were  detected at 5-minute 
intervals for at least 90 minutes (NovoStar plate reader, BMG Labtech). Values of optical 
density were plotted against the time of reaction and straight linear regression line was 
fitted to it.  Fitting and results were accepted at r2 >0.90. ACE activity was calculated as 
follows: 
ACE activity =  -(S/k)xD 
in which S is the rate of decrease in optical density (1 per minute),  k is the change in optical 
density until the splitting of  1 nmol of FAPGG is complete and D is serum dilution. ACE 
activity was given in units (U); 1 U equals 1 nmol FAPGG splitting per minute. The inhibiting 
effect of captopril (ACE inhibitor) on human serum ACE was examined in the 0.1 nM-1.0 mM 
concentration range. 
Measuring serum ACE concentration  
Serum ACE concentration was measured using a commercially available ACE ELISA kit (R&D 
Systems). The plates had been coated with 80 ng/well anti-ACE antibodies and the remaining 
binding sites were blocked using inert proteins in Dulbecco’s phosphate-buffered saline 
solution.  Using diluted reagent, we added 100-times-diluted serum to the surface and 
introduced antibody-antigen complexes labelled with biotinylated detection antibodies into 
the wells. Eventually, the quantity of complexes was detected using a substrate solution 
containing 0.3 mg/ml of tetramethylbenzidine, 0.1M of H2O2 and 50 mM of acetic acid. The 
reaction was terminated in 20 minutes, by the addition of 0.5 M of hydrochloric acid. Optical 
density was measured at 450 nm. The result of serum ACE expression was given as the 
quantity of ng ACE/ml serum. 
Calculating ACE activity in undiluted human serum 
ACE activity in undiluted serum was calculated using the formula below:  
Ki=([Active ACE]x[HSA])/[Inactive ACE] 
Ki is the constant of HSA inhibition (83 µM). [Active ACE] means the concentration of active 
forms of ACE. [Inactive ACE] stands for the concentration of the inhibited forms of ACE, 
while [HSA] represents human serum albumin concentration  determined using colorimetry. 
In the calculations the following were regarded: 
[Full ACE quantity] = [Active ACE] + [Inactive ACE], in which [Full ACE quantity] was measured 
using ELISA, 
[Active ACE] = (Ki x [Full ACE quantity]) / ([HSA] + Ki). 
In order to assess activity in undiluted human serum, ACE activity was measured in the 
samples of the same patient, the dilution being 20 times, which was related to [Active Ace] 
and in that case ACE activity was regarded  uninhibited by HSA. 
Collecting human tissue samples during bypass surgery  
A prospective study was conducted in order to examine angiotensin conversion in human 
vascular tissue. Blood samples and distal segments of the saphenous vein and mammary 
artery were collected from patients having undergone coronary bypass surgery. The study 
involved 76 patients. The medical team consisted of four cardiac surgeons who harvested 
vascular grafts using the same technique. Still in the operating theatre, extra grafts left over 
from operations were immersed into ice-cold physiological saline solution (KREBS solution) 
and transferred to our laboratory. These tissue samples were used in functional 
measurements (to measure isometric contractile force) as well as to determine ACE 
expression in the tissues. Vessel samples were cut into circular, ring-like preparations of 4 
mm in width and put into ice-cold oxygenated physiological saline solution (KREBS)   for 
further functional examinations. Some were dried and frozen for biochemical tests. Blood 
samples were collected in order to determine ACE genotype and serum ACE. 
 
Measuring vasoconstriction in bypass grafts  
The aforementioned vessel rings were fixed and their contractility was measured in an 
isometric contractility measuring system (DMT 510A, Danish Myotechnology). Smooth 
muscle functions and endothelial integrity were tested after the addition of 30 M 
norepinephrine and 10 M methacholine, respectively. Vascular contractility was tested 
using angiotensin I and II (both manufactured by Sigma-Aldrich) in increasing concentrations. 
In many  cases, tests were also performed by adding type 1 angiotensin II blocker (AT1R) – 
telmisartan  1.0-10 nM – while in other cases, type 2 angiotensin II receptor  blocker (AT2R) 
–  10 M of PD123319 – as well as ACE inhibitor, captopril (0.1-100 M),  and chymase 
inhibitor, chimostatin (300 M ), were added. (All of the chemicals were produced by Sigma- 
Aldrich). Contractility response was either compared to the maximum effect caused by the 
medicine or the maximum effect of norepinephrine achieved prior to treatment with 
angiotensin. 
Measuring tissue ACE expression in patients after bypass surgery  
The frozen vessel samples were homogenized and separated in a centrifuge (at 16,000 g, 
4°C, for 5 minutes). The supernatant had been collected and stored frozen (-20 °C) before 
the measurements. ACE concentration was determined using the Human ACE ELISA system 
(described above), following the manufacturer’s protocol (R&D) closely. At least two 
independent measurements were used on average in order to assess ACE concentration, 
while protein determination was based on three parallel measurements. The expressed 
quantity of ACE was given in ng ACE/mg protein units. 
Determining the I/D polymorphism of ACE 
Genomic DNA was isolated from leukocytes of peripheral blood using FlexiGene® DNA Kit 
(Qiagen). The insertion/deletion (I/D) polymorphism of ACE was determined by the PCR 
amplification of alleles I and D, according to the standard protocol elaborated by Rigat et. al. 
(Rigat et. al. 1992). The products obtained by amplification were separated by 
polyacrylamide gel electrophoresis and visualized using ethidium bromide staining. The 
presence of  I or D alleles  was detectable in products of 490 bp or 190 bp obtained by PCR. 
Statistical analysis 
We carried out one-way ANOVA using Graphpad Prism software (GraphPad Software) 
supported by Dunnett multiple comparison test and t-test,  the differences of p<0.05 being 
regarded significant. On examining the relationship of continuous clinical parameters, we 
used regression analysis. 
 
RESULTS  
 
ACE genotypes of blood samples obtained for human serum albumin 
investigations in view of morphometric and laboratory parameters, and the drugs 
used 
Blood samples from 151 hypertensives were collected. Based on the I/D genotype of ACE, 
they were divided into three groups (DD, ID, II). The most important morphometric 
parameters, such as distribution according to gender, age, body mass index, smoking habits, 
left ventricular systolic ejection fraction, systolic and diastolic pressure, and heart rate were 
included in a table. Presence of diabetes and hyperlipidaemia, current total cholesterol level 
and the most important parameters of renal function (serum urea, creatinine and 
glomerular filtration rate) were also recorded. We divided antihypertensive medicines 
commonly taken by the patients into three groups but found no significant statistical 
differences among the groups. 
Relationship between serum ACE concentration and activity 
First, we checked the endogenous ACE inhibiting potential of human serum albumin (HSA). 
We mapped ACE activity as the functioning of the serum angiotensin converting enzyme, 
which showed linear correlation in both individual patients and groups of patients with 
different endogenous ACE expression. But the five-fold rise in serum ACE concentration 
resulted in only 2.3-fold elevation in serum ACE activity. Accordingly, the rise of serum ACE 
concentration from 6211 ng/ml to 25232 ng/ml (elevation in expression by 4.1 times) was 
accompanied with partial elevation in ACE activity (by 2.1 times) from 277 U/ml to 562 
U/ml. 
Decisive role of ACE genotype in serum ACE concentration and activity  
In patients homozygous to the D (deletion) allele of the ACE gen, higher serum ACE 
concentration could be detected compared to those who were homozygous to the I 
(insertion) allele (Insertion, II=47-194 ng/ml; mean: 94.5 ng/ml, n=28, ID=36-202 ng/ml, 
mean: 112.9 ng/ml, n=70, DD=74-188 ng/ml, mean: 154.9 ng/ml n=53). ACE activity was also 
elevated in DD homozygous patients (II=15.6-55.4 U/ml, mean: 32.74 U/ml, n=28, ID =15.2-
59.3 U/ml, mean: 35.94 U/ml, n=70, DD=27.3-59.8 U/ml, mean: 42,95 U/ml, n=53). Overall, 
elevation of serum ACE concentration by 64% was accompanied with only 31% rise in ACE 
activity compared to patients of genotype II. 
Role of serum albumin concentration in controlling serum ACE activity      
These data suggest that, in addition to human serum ACE concentration, ACE activity is 
controlled by further factors. Based on our earlier results we have presumed that human 
serum albumin acts as a certain kind of ACE inhibitor which has a concentration-dependent 
effect on serum ACE activity.  In in vitro trials, we tried to find correlation between serum 
albumin concentration and serum ACE activity in human serum. Specific ACE activity was 
higher in case serum albumin concentration was decreased owing to the dilution of the 
serum. ACE activity decreased from 56.13±1.17 U/ml to 38.55±0.78 U/ml if HSA 
concentration rose from 2.42±0.02 mg/ml to 12.12±0.12 mg/ml. In relation to human serum 
ACE-HSA, the constant of stability was (Ki) 5.7±0.7 mg/ml, which was suggestive of ACE 
activity of 8.47±0.18 U/ml (calculated values) in the presence of 48.46±0.46 mg/ml HSA. 
Examining the relationship between morphometric parameters and serum ACE 
concentration  
We have tested if the endogenous inhibitory effect of HSA on serum ACE is suitable to 
compensate for the differences in ACE expression levels in patients suffering from 
hypertension in whom therapeutic ACE inhibition has been partly effective. A sample of 
patients (n=151) on ACE inhibition were included in the study. Serum ACE concentration 
showed no relationship with amorphometric parameters, e.g. age, body weight and height 
or body mass index. 
Examining the relationship between serum lipid levels and serum ACE 
concentration  
Total cholesterol and triglyceride levels were checked and plotted against the function of 
serum ACE concentration (n=151 patients).  A straight linear regression line was fitted to the 
points in order to find the possible correlation among the parameters in the graph. The 
normal values of total cholesterol and triglyceride were 5.2 mmol/l and below 1.7 mmol/l, 
respectively.  Serum ACE concentration showed no relationship with total cholesterol or 
triglyceride levels. 
Examining the relationship between serum ACE concentration and cardiovascular 
parameters  
Systolic and diastolic parameters (ejection fraction, heart rate, systolic and diastolic 
pressure) were plotted against serum ACE concentration (n=151). Ejection fraction, heart 
rate, and systolic and diastolic pressure were regarded normal above 50%, between 60-
100/min, and in the range of 90-140 mmHg and 60-100 mmHg, respectively. Cardiovascular 
parameters (ejection fraction, heart rate, systolic and diastolic pressure) were also 
independent of serum ACE concentration, due to inaccurate fitting (based on low r2 values). 
Relationship between serum ACE concentration and renal function parameters   
Renal functions were established on the basis of the mean serum concentrations of 
creatinine and uric acid and using the glomerular filtration rate (GFR). Values were given in 
the function of serum ACE concentration (n=151). Normal values were as follows:  urea 3.6-
7.2 mmol/l, creatinine 44-97 mol/l (female) and 62-106 mol/l (male), GFR below 90 
ml/min/1.73m2, uric acid 140-340 µmol/l (female) and 220-420 µmol/l (male). Renal function 
parameters (serum urea, creatinine and glomerular filtration rate) were widely scattered 
(low r2  values), denying correlation with serum ACE concentration. 
Relationship between the patients’ parameters and I/D genotype of ACE 
Different parameters (age, weight, body mass index, total cholesterol, triglyceride, ejection 
fraction, heart rate, systolic and diastolic pressure, urea, creatinine, glomerular filtration rate 
and uric acid) were correlated with the patients’ genotypes (insertion: II, n=28, deletion: DD, 
n=53, and heterozygous: ID, n=70).  Like above, no relationship was found between these 
clinical parameters and genotype of ACE or the individual ACE expression levels. 
Analysis of the distribution of samples from the saphenous vein and radial artery  
in view of morphometric and laboratory parameters and the drugs used 
Further investigations were targeted at patients having undergone bypass surgery. Samples 
of the radial artery (120 segments from 31 patients) and saphenous vein (148 segments from 
45 patients) were harvested from a total of 76 patients. The most important morphometric 
parameters such as distribution according to gender, age, body mass index, systolic and 
diastolic pressure and heart rate were included in a table. In addition to checking cholesterol 
and triglyceride levels, as well as fasting blood glucose concentration, we analyzed the 
presence of diabetes and the NYHA status at the time of surgery. Common, preoperatively 
administered primary and secondary prophylactic medicines were also included in the table. 
No significant statistical differences were found between the two groups. 
Contractile responses to angiotensin I and angiotensin II  
Our investigations were aimed at characterizing ACE in the tissues via checking the effect of 
vasoconstriction, ACE expression and ACE activity with regard to tissue specificity (radial 
artery and saphenous vein grafts) and genotype. Treatment with angiotensin II (Ang II) 
caused significant vasoconstriction in both the samples from the radial artery and segments 
of the saphenous vein. Vasoconstriction in samples from the radial artery (82±6%, n=30) was 
significantly higher (p<0.01) compared to the relevant parameters for the saphenous vein 
(61±5%, n=39). Maximum vasoconstriction was assessed after the addition of 30 µM 
norepinephrine. Although the differences in maximum vasoconstriction responses were 
quite significant to Ang II, Ang II sensitivity was also much higher in samples from radial 
arteries (p<0.01) compared to those from saphenous veins (3.0±0.5 nM, p=31 and 6.6±0.9 
nM, p=36, respectively). Preliminary treatment with the type 2 angiotensin  receptor II 
(AT2R) inhibitor (PD123319 10 µM) caused no change in Ang II sensitivity in radial arteries 
(EC50=4.4±0.7 nM, n=27)  or saphenous veins (EC50=8.2±2.0 nM, n=25), therefore it was 
concluded that AT2R played a limited role in triggering vascular responses in such 
experimental systems. 
Responses to Ang I were measured in order to examine the conversion of Ang I to Ang II in 
the tissues. The effect of Ang I at half maximum was EC50=31±6 nM, (n=26) on the radial 
artery while it was found 30±4 nM (n=40) in the saphenous vein. As the effect of Ang I on 
tissues develops after it is converted into Ang II, the above experimental results suggest 
significant conversion of Ang I into Ang II in the tested vessels. We have calculated the 
proportion of Ang I and Ang II effect (EC50), to quantify the extent of the conversion of Ang I 
into Ang II. This effect was significantly lower (p=0.02) in the samples of the radial artery 
(0.17±0.03, n=23) compared to that of the saphenous vein samples (0.51±0.14, n=24). These 
results show three times more effective Ang I conversion in the saphenous veins than in the 
radial arteries. 
 
Mechanisms of angiotensin-induced vasoconstriction  
The results have also confirmed that the Ang I effect is triggered by the local conversion of 
Ang I into Ang II in the saphenous veins. Responses to the dose-dependent inhibition of Ang 
II (1.0 nM-10 nM) by telmisartan suggest that the Ang II effect involves type 1 angiotensin II 
receptors (AT1R). Similarly, by administering telmisartan we could inhibit vasoconstriction 
induced by Ang I and concluded that the effect of Ang I was also communicated by means of 
the AT1R receptors.  We also examined the identity of angiotensin I converting enzyme. 
After the addition of captopril (100 µM), widely known for its effect to inhibit the  
angiotensin converting enzyme (ACE), there was substantial decrease  in the response to Ang 
I, which supports the role of captopril in ACE conversion. Moreover, Ang I was also inhibited 
by simultaneously adding 100 µM of captopril and 300 µM of chymastatin, a chymase 
inhibitor. Results suggest, that chymastatin can be successfully used if Ang I is present in 
higher concentrations.  
Examining the inhibitory effects of captopril on circulatory and tissue ACE 
The inhibitory effects of captopril on both circulatory and tissue ACE were examined in 
detail. First, we could confirm circulatory ACE inhibition in circulatory ACE. Significantly 
lower (p<0.01) serum ACE activities (7.0±1.0 U/l, n=15) were measured in patients treated 
with ACE inhibitors compared to ACE activities in untreated patients (22.0±2.0 U/l, n=15). 
Next, the effect of captopril on human tissue ACE was tested in vitro. Based on the results it 
was evident, that captopril was capable of completely inhibiting human serum ACE at 15 nM 
(IC50). We also tested the converting effect of captopril on tissue angiotensin I in order to 
assess the inhibitory potential of this drug on tissue ACE. Captopril was ineffective at a 
concentration of 1 µM, but concentrations of 10 µM and 100 µM had non-competitive 
inhibitory effects. 
 
Expression of angiotensin converting enzyme in blood circulation (serum) and 
tissues (saphenous vein) 
ACE expression was measured in both tissue samples.  Twice as high ACE expression was 
detected in saphenous veins as in tissues from the radial artery (5.3±0.7 ng/mg tissue 
protein, n=14 in the radial artery and 9.7±1.0 ng/mg, n=35 tissue protein in samples from the 
saphenous vein, p<0.01). These results are in harmony with the threefold Ang I conversion 
efficiency. In contrast, no difference in ACE concentration was detected in the specific 
patients’ blood samples (p=0.12, serum ACE concentration in samples from the radial artery: 
164±21 ng/ml n=14, whereas in samples from the saphenous vein: 134±10 ng/ml, n=34). 
ACE expression in tissues and circulation depending on the ACE genotype  
Other research teams have also suggested serum ACE expression is controlled by genetic 
polymorphism. In our study, we have also managed to support this hypothesis about ACE 
expression.  In patients of the DD genotype, serum ACE expression has been significantly 
higher than in those of the II genotype (171±15 ng/ml, n=13, and 97±15 ng/ml, n=11, 
respectively, p<0.01). However, in the samples from the saphenous vein from the same 
patients, no relationships determined by the same genetic polymorphism in the background 
of tissue ACE expression has been detected (9±1 ng/mg, n=11 in genotype II and 9±1 ng/mg 
in genotype DD, n=13). Further detailed research has demonstrated that tissue (from the 
saphenous vein) and serum ACE concentrations are regulated independently of each other 
(the results cannot be fitted with a straight line of linear regression; in the best fit: r2=0.014, 
n=35). 
Accordingly, human serum ACE expression has been detected in a very wide range (47-288 
ng/ml) and it was found 64% higher in patients of the DD genotype than of the II genotype. 
The obviously missing correlation between cardiovascular parameters and ACE expression 
(genotype) is surprising, especially because the cardiovascular efficiency of ACE inhibitors is 
supported by several clinical studies on large samples, and approved guidelines. In view of 
previous data we have presumed that the differences in ACE expression, associated with the 
I/D polymorphism of ACE,  may play a role  in the development of  myocardial infarction, 
coronary diseases, sclerosis of the coronary arteries, cardiac failure and hypertension. We 
could not detect a similar relationship, which was in agreement with the results of a meta-
analysis including more than 30 000 subjects.  
In the present study we have directly tested the relationship between ACE expression and 
ACE activity in the serum of hypertensives. We have found that the serum ACE concentration 
of patients of the DD genotype was 64% higher than those of the II genotype; the difference 
in ACE activities was only 31%, suggesting that higher ACE expression is buffered under 
physiological conditions. Our observations are in agreement with the ones according to 
which the local conversion of angiotensin I into angiotensin II and the II/I proportion of 
angiotensin are independent of the genotype in human samples. 
It is important to remark that the issue is more complicated than just determining serum 
ACE activity accurately. It is partly due to the fact that previous investigations informed 
about the significant effect of diluting the serum on the values of ACE activity. In order to 
reduce such effect the use of a high dilution factor is recommended. This is consistent with 
the results by our team as we have identified serum albumin as an endogenous ACE inhibitor 
at Ki = 5.7±0.7 mg/ml. According to our experience, if serum albumin is removed from the 
human serum, the actual serum ACE activity is higher and there is no dilution effect. 
The novelty of our study is that it demonstrates the inhibitory effect of serum albumin on 
ACE in clinical circumstances. In addition to the 4.1-fold elevation in the ACE concentration 
in the patients’ sera, there was a 2.1-fold rise in ACE activity, which suggests that serum ACE 
activity is under control. In addition to enzyme concentration, other factors also contribute 
to ACE activity.  These factors may suppress ACE activity at different levels of ACE expression 
if the presence of a mechanism to stabilize endogenous ACE activity is presumed.  
Suppression may be clinically significant even if circulatory ACE levels are elevated due to 
genetic factors (e.g. I/D polymorphism of ACE) or disease. Point mutation arising from the 
saar region of the ACE gene, can cause five-fold increase in circulatory ACE concentration. 
Several other mutations of the ACE gene are accompanied by mild elevation in ACE 
concentration without causing increase in the incidence of cardiovascular diseases. All these 
observations suggest that the significant differences in ACE concentration can be well 
tolerated. This is explained by the fact that ACE activity is stabilized by endogenous factors at 
a lower level. Our group’s earlier results justified HSA being such an endogenous ACE 
inhibitor. The present study was aimed to examine to what extent human serum albumin in 
human serum samples was responsible for the inhibition of the ACE gene. ACE activity can 
be determined in the presence of a specific amount of HSA (e.g. 56±14 U/ml 2.4±0.3 mg/ml 
of HSA) but it decreases, in correlation with the ACE-inhibiting potential of HSA, if the 
concentration of HSA is increased. 
Unfortunately, direct measurements of ACE activity were impossible in undiluted serum. ACE 
activities were measured after four-fold dilution as the serum has substantial power to 
absorb light at 340 nm, which does not allow us to measure the conversion of the specific 
substrate. ACE activity was assessed in undiluted serum by measuring serum albumin and 
ACE concentrations. In the assessment we also used the results of ACE activity measured at 
20-fold dilution and using the HSA constant (Ki= 5.7±0.7 mg/ml), determined in human 
serum earlier. Considering these measurements and calculations – based on our results – the 
ACE activity in human serum can be approximately 8.5±2.2 U/ml. 
ACE (127 ng/ml) and serum albumin (48 mg/ml) concentrations measured in human serum 
by us suggest that the differences in ACE concentrations are caused by the buffer effect of 
HSA. Serum albumin is present in a concentration ten times higher than the ACE-inhibiting Ki 
quantity of HSA. The results of these measurements have been suggestive of ACE being 
present in circulation in a significantly inhibited form, dependent on HSA. 
Suppression of serum activity can serve as a basis for important conclusions in practice. In 
case of in vivo endogenous ACE inhibition to a great extent, physiological angiotensin II 
concentration can be profoundly affected by the elimination of angiotensin II. In that case, 
RAAS activation, serving as the basis for cardiovascular diseases (hypertension, cardiac 
failure), can be caused by decreasing elimination of angiotensin II.  ACE2 is one of the best 
characterized enzymes which plays a role in the elimination of angiotensin II; and, as the 
latest findings suggest, its activation provides protection against hypertension, myocardial 
fibrosis, remodelling and renal damage. In accordance with the above, our research team 
has also confirmed the role of ACE2 between hypertension and the systolic function of the 
heart. 
Based on another conclusion, serum albumin concentration can also have an effect RAAS 
function via the modulation of ACE activity.  The results support that ACE is well suppressed 
until serum albumin concentration is found to be at least 30 mg/ml. Nonetheless, human 
serum albumin concentration may decrease below the aforementioned level, e.g. in both 
protein malnutrition and renal failure. Also based on our findings, it can be proposed that 
administering serum albumin intravenously we can increase ACE inhibition.  This has been 
supported by the observation that postoperative human serum albumin given intravenously 
has often caused hypotension in patients receiving ACE inhibiting therapy. 
Further research was carried out in human vascular samples, such as the saphenous vein and 
radial artery to examine tissue ACE in samples for patients having undergone coronary 
bypass graft surgery (CABG). 
Long-term survival in patients after bypass surgery is greatly influenced by the conductivity 
of the graft, which, on the other hand, is dependent on vascular tissue type. Arterial grafts 
survive longer than those from the saphenous vein. Due to the short survival of saphenous 
vein grafts there has been growing demand for a graft-specific treatment by which the 
uneventful postoperative period of patients after CABG-surgery could be extended. In order 
to devise a graft-specific treatment, one has to understand factors affecting the much 
greater vulnerability of saphenous grafts compared to the radial artery. In the first 
postoperative month, early degeneration of the saphenous grafts is caused by thrombolytic 
occlusion. Later, processes involving atherosclerotic obstruction associated with neointimal 
hyperplasia play a dominant role. Angiotensin converting enzyme (ACE) can play a role in 
these processes because ACE inhibition deceases thrombocyte aggregation, improves 
endothelial function and moderates neointimal growth. Several studies in the past (QUO 
VADIS, APRES, HOPE) also reported significant improvement after ACE inhibiting treatment. 
The study entitled IMAGINE, however, challenged the useful effects of ACE inhibition in the 
treatment of patients after bypass surgery. All of these contradicting results have urged us to 
precisely devise and execute our examinations.  
We put a lot of effort into trying to confirm the importance of ACE effect on saphenous 
grafts.  We compared tissue samples from the saphenous vein and radial artery. Based on 
the results, angiotensin converting enzyme expression was double and the conversion of 
angiotensin I into angiotensin II (Ang I into Ang II) was  two and a half time more effective in 
samples from the saphenous veins than in the ones from the radial arteries. 
We have made further efforts to compare angiotensin converting enzyme in circulation and 
bound in tissues. We have presumed that determining circulatory ACE activity can help us to 
assess individual risks and tailor the treatment to the individual.  Interestingly enough, we 
could not find a relationship between the expression of circulatory ACE or tissue ACE. This 
striking observation can be explained as follows: circulatory ACE expression is determined by 
a genetic polymorphism but no such background could be detected in the case of tissue ACE 
expression. This observation can also explain that ACE levels (ACE polymorphism) are not of 
great significance in different cardiovascular diseases, while, in the same group of patients, 
ACE inhibitors represent a wide therapeutic arsenal of agents. But beyond that, we have 
found substantial differences in the quantities of ACE in circulation (serum) and in the tissues 
(saphenous vein) after inhibition using captopril. Captopril was capable of inhibiting serum 
ACE at 15 nM, while tissue ACE inhibition could be achieved by administering the drug in 
doses a thousand times higher (10 M). 
Values of tissue ACE activity were given on the basis of functional measurements. The 
conversion of Ang I into Ang II was examined in graft tissues obtained prior to bypass 
surgery.  It should be remarked that local ACE levels and ACE activity were determined from 
venous blood drawn theoretically at the same time with graft implantation. 
Finally, mention must be made of the limitations of our study. Putting experimental results 
into clinical practice appeared to be the greatest challenge for us. While captopril could 
effectively inhibit serum ACE activity in an order corresponding to the physiological range, it 
was less effective on tissue ACE inhibition. These observations suggest that certain ACE 
inhibitors are ineffective in inhibiting ACE activity in grafts from the saphenous vein. 
Therefore they mask or veil the results of clinical tests performed to prevent the 
degeneration of saphenous vein grafts. Moreover, graft permeability can be beneficially 
influenced by higher ACE activity: increased tonicity of the vessels mediated by angiotensin II 
contributes to the rate of blood flow through them causing decrease in local haemostasis. 
On the other hand, increased angiotensin II levels can activate neurohormonal mechanisms, 
making the picture even more complicated.  Last but not least, the permeability  and 
rheological characteristics of saphenous veins implanted into coronary circulation change 
significantly. It would probably highlight the issue of graft permeability, improving due to the 
effect of ACE inhibitors, if we could carry out further  tests to compare two different ACE 
inhibitors, one of which has a selective effect on ACE found in the tissue of the saphenous 
vein. In a constellation like that, complications due to the beneficial effects of systemic ACE 
inhibition (e.g. consequences of the effect on volume homeostasis and renal metabolism) 
could be avoided. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY  
Angiotensin converting enzyme (ACE) inhibitors rank fifth among the most commonly 
prescribed groups of drugs; they serve as baseline medicines in the treatment of 
cardiovascular diseases.  
In a previous study we identified serum albumin as an endogenous ACE inhibitor at Ki = 
5.7±0.7 mg/ml. If serum albumin was removed from the human serum, specific serum ACE 
activity was higher. The novelty of our study is that it demonstrates the inhibitory effect of 
serum albumin on ACE in clinical circumstances. Serum ACE activity showed incomplete 
correlation with ACE concentration. In addition to a 4.1-fold elevation in the ACE 
concentration in the patients’ serum, there was a 2.1-fold rise in ACE activity, which 
suggested that serum ACE activity was under control. In addition to enzyme concentration, 
other factors also contribute to ACE activity.  A factor like that may suppress ACE activity at 
different levels of ACE expression if the presence of a mechanism to stabilize endogenous 
ACE activity is presumed.  We also investigated the importance of the effect of angiotensin 
converting enzyme on grafts from the saphenous vein.  We compared samples from the 
saphenous vein and radial artery.  Twice as high angiotensin converting enzyme (ACE) 
expression and 2.5 times more effective tissue conversion from angiotensin I into 
angiotensin II were found in the more vulnerable saphenous veins, compared to the findings 
in the radial arteries. In saphenous veins, tissue ACE expression was independent of the ID 
gene polymorphism of ACE, which was in contrast with the serum ACE concentration in the 
same patients, due to the regulatory role of gene polymorphism detected in the background. 
The expression of ACE in the serum and tissues represents independent processes.  The 
inhibitory potentials of captopril on tissue and serum ACE differ significantly. 
In summary  it can be concluded  that the inhibition of physiological ACE activity using HSA 
can contribute to tolerating different ACE expression levels determined by the I/D 
polymorphism of  ACE, and, consequently, a decrease in the probable incidence of various 
cardiovascular diseases. The importance of ACE inhibiting treatment is given special 
attention in  case patients receive saphenous vein grafts: the use of a tissue-specific ACE 
inhibitor can improve the permeability of saphenous vein grafts. 
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